Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

The patient can understand the research and sign the informed consent.
Without a history of other malignancies before enrollment, except for non-melanoma skin cancer, in situ cervical cancer;
18≤Age≤65;
...
The patient can understand the research and sign the informed consent.
Without a history of other malignancies before enrollment, except for non-melanoma skin cancer, in situ cervical cancer;
18≤Age≤65;
ECOG performance status of 0 or 1;
Pathological diagnosis with Stage IIIA-N2 NSCLC which is clinically resectable and the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT;
WBC≥4.0×109/l, ANC≥1.5×109/l, PLT≥100.0×109/l, Hb≥90g/l;hepatorenal function is normal;

Exclusion Criteria

Have received other treatment within the last 30 days before enrollment;
Female in pregnancy or lactating;Female of childbearing age without contraception;
With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).
...
Have received other treatment within the last 30 days before enrollment;
Female in pregnancy or lactating;Female of childbearing age without contraception;
With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).
With a significant history of neurological of psychiatric disease,including the dementia which may affect the ability to understand and sign the informed consent;
With acute infection or other serious underlying disease;

Summary

Conditions
Non Small Cell Lung Cancer Stage IIIA
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Non-Randomized
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Description

Scheme: Patients will receive different chemotherapy regimens depending on the pathological type. Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Docetaxel/Cisplatin 2 cycles. Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concur...

Scheme: Patients will receive different chemotherapy regimens depending on the pathological type. Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Docetaxel/Cisplatin 2 cycles. Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Pemetrexed/Cisplatin 2 cycles.

Inclusion Criteria

The patient can understand the research and sign the informed consent.
Without a history of other malignancies before enrollment, except for non-melanoma skin cancer, in situ cervical cancer;
18≤Age≤65;
...
The patient can understand the research and sign the informed consent.
Without a history of other malignancies before enrollment, except for non-melanoma skin cancer, in situ cervical cancer;
18≤Age≤65;
ECOG performance status of 0 or 1;
Pathological diagnosis with Stage IIIA-N2 NSCLC which is clinically resectable and the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT;
WBC≥4.0×109/l, ANC≥1.5×109/l, PLT≥100.0×109/l, Hb≥90g/l;hepatorenal function is normal;

Exclusion Criteria

Have received other treatment within the last 30 days before enrollment;
Female in pregnancy or lactating;Female of childbearing age without contraception;
With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).
...
Have received other treatment within the last 30 days before enrollment;
Female in pregnancy or lactating;Female of childbearing age without contraception;
With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).
With a significant history of neurological of psychiatric disease,including the dementia which may affect the ability to understand and sign the informed consent;
With acute infection or other serious underlying disease;

Locations

Hangzhou, Zhejiang, 310022
Hangzhou, Zhejiang, 310022

Tracking Information

NCT #
NCT01926483
Collaborators
Not Provided
Investigators
  • Principal Investigator: Weimin Mao, MD Zhejiang Cancer Hospital
  • Weimin Mao, MD Zhejiang Cancer Hospital